Finance

Lists
FLNA:BMV
Filana Therapeutics Inc
MX$ १५.९२
०.००%
(०.००) 1D
अक्टोबर ५, १२:०५:३१ GMT-६  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for FLNA...
Mkt. cap
३.४० करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
MX$ ५६.००
52-wk low
MX$ १५.९२
No. of employees
१९
Mkt. cap
३.४० करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
MX$ ५६.००
52-wk low
MX$ १५.९२
No. of employees
१९
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
२८ मिनेट पहिले
Five Year MS Data Might Change The Case For Investing In TG Therapeutics Stock (TGTX)
WSJ
WSJ
·
१० घण्टा पहिले
U.S. Stocks Fall as Credit Fears Haunt Tech Sector
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
About Filana Therapeutics Inc
CEO-
Employees१९
Founded१९९८
Headquartersअस्टिन, टेक्सस, संयुक्त राज्य अमेरिका
Sector-
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
३९.५५ लाख
३८.५३ लाख
४५.४४ लाख
३३.०३ लाख
Cost of revenue
३९.५५ लाख
३८.५३ लाख
४५.४४ लाख
३३.०३ लाख
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७९.०५ लाख
५६.९९ लाख
६६.२४ लाख
६०.९० लाख
Operating expense
७९.०५ लाख
५६.९९ लाख
६६.२४ लाख
६०.९० लाख
Total operating expenses
१.१९ करोड
९५.५२ लाख
१.१२ करोड
९३.९३ लाख
Operating income
-१.१९ करोड
-९५.५२ लाख
-१.१२ करोड
-९३.९३ लाख
Other non operating income
-१.१४ लाख
३९.०० हजार
४८.०० हजार
४३.०० हजार
EBT including unusual items
-१.०८ करोड
-१.२५ करोड
-१.०३ करोड
-८६.०३ लाख
EBT excluding unusual items
-१.०८ करोड
-८५.३९ लाख
-१.०३ करोड
-८६.०३ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.०८ करोड
-१.२५ करोड
-१.०३ करोड
-८६.०३ लाख
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
११.६७ लाख
९.७४ लाख
७.८९ लाख
७.४७ लाख
Interest expense
-
-
-
-
Net interest expenses
११.६७ लाख
९.७४ लाख
७.८९ लाख
७.४७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.१७ करोड
-९१.८५ लाख
-१.०९ करोड
-९१.४९ लाख
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google एपहरू